17 September 2016

Encouraging results for siponimod in secondary progressive MS trial

Siponimod reduced the risk of progression in secondary progressive MS (SPMS) according to results presented at the ECTRIMS meeting in London on 17 September.

Woman with MS and MS nurse
05 September 2016

MS Trust launches campaign to fund new MS nurses in areas of greatest need

A new report from the MS Trust shows that two in three people with MS in the UK live in areas where there aren’t enough MS nurses to provide vital care and support.

26 August 2016

Encouraging results in secondary progressive MS trial

Initial research results suggest siponimod may slow progression in people with secondary progressive MS

25 August 2016

Improving access to information for those with long-term conditions

The Patient Information Forum (PIF) are looking for people living with MS who may be interested in taking part in a focus group for its ‘perfect information journey’ project focused on improving access to information for patients with long-term conditions.

17 August 2016

GPs lack confidence in assessing and referring people with symptoms of MS

People experiencing the first signs and symptoms of neurological conditions like MS are waiting too long to see an appropriate specialist, according to over 1,000 GPs surveyed across the UK.

21 July 2016

Vitamin D - new guideline recommends daily intake of 10 micrograms for the general population

A government report published today recommends that everyone should aim to consume 10 micrograms of vitamin D (400 IU) each day to ensure healthy bones and muscles.

07 July 2016

Daclizumab (Zinbryta) gets European licence for relapsing forms of multiple sclerosis

The European Commission (EC) has granted marketing authorization for daclizumab (Zinbryta) for the treatment of adults with relapsing forms of multiple sclerosis. This follows a recommendation from the European Medicines Agency in May that a licence should be granted.

30 June 2016

Major national survey of neurological conditions launches today

A national survey of people living with a neurological condition, including multiple sclerosis, launches today. The Neurological Alliance, representing 80 organisations working across England to improve life for people living with a neurological condition, is running their second neurological patient experience survey.

20 June 2016

New report calls for neurology care to be delivered closer to home

The Thames Valley Strategic Clinical Network launches a new report calling for improvements in neurological services provided in the community.

09 June 2016

Research shows longer term benefits from stem cell therapy

Results from two trials of an aggressive form of stem cell therapy indicate the treatment may have long-term benefits.

08 June 2016

Disappointing results from opicinumab (anti-LINGO-1) study

Preliminary results announced in a company press release report that opicinumab (also known as anti-LINGO-1 and BIIB033) failed to improve disability, assessed by a combination of physical and cognitive measures.

02 June 2016

Gene discovered that can increase risk of rare form of progressive MS

Researchers in Canada have identified a gene that appears to significantly increase the risk of developing a rare rapidly progressing form of MS. 

01 June 2016

Fasting-mimicking diet studied as potential MS treatment

A diet that mimics the effects of fasting may have a role in managing MS according to new research.

Study finds poor integration
26 May 2016

Study finds poor integration between neurology and palliative care teams

A study has found wide variation in how much palliative care and neurological teams provide joined-up services at eight sites in England and Wales. There was least coordination in services for people with MS.

25 May 2016

Fatigue and lack of support affect employment with MS

An international survey shows that too many people with MS are leaving employment earlier than necessary.

04 May 2016

Daclizumab moves closer to approval for relapsing MS

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended that a licence should be granted for daclizumab for the treatment of relapsing MS.

Qudos logo
28 April 2016

Calling all MS health professionals: enter or nominate colleagues for the 2016 QuDoS in MS awards!

We're pleased to announce that, after a hugely successful first year, the QuDoS awards, highlighting innovation and excellence in MS services, are now open for nominations for 2016.

Latest news from the MS Trust
20 April 2016

MS Trust report finds people with progressive MS feel like they're getting a second class service

According to a new report published today by the MS Trust, growing pressures on NHS services mean people with progressive MS get much less support from specialist health professionals than people with relapsing remitting MS. As well as seeing health professionals less frequently, many people with progressive MS report being ‘abandoned’ by specialist services just as they enter the progressive phase of the disease, marked by complex symptoms and increasing disability.

04 March 2016

Young people with MS being cared for in older people’s care homes

Hospice and neurological rehabilitation charity Sue Ryder estimates that a lack of dedicated neurological care and rehabilitation services in Scotland means that up to 1,000 people are being cared for in inappropriate settings.

04 March 2016

Drinking coffee may reduce the risk of developing multiple sclerosis

Researchers have reported that people drinking more than 900 ml of coffee each day, roughly equivalent to three average-size mugs, are up to 30% less likely to develop multiple sclerosis than people who drink no coffee.

02 March 2016

Recommendations for minimising the risk of PML with Tysabri.

Recommendations from the EMA to reduce the risk of PML for those at high risk taking the multiple sclerosis disease modifying drug Tysabri (natalixzumab) suggest increasing the frequency of MRI scans.

01 March 2016

Parliamentary committee issues wake-up call over neurology services

Last week the Public Accounts Committee has published its report into services for people with neurological conditions. The report by the influential parliamentary committee recognises the ongoing challenges facing neurology services finding that, despite a similar review in 2012, there is still “wide variation across the country in access, outcomes and patient experience.”

19 February 2016

Participants still needed for MS-SMART secondary progressive MS trial

The MS-SMART trial will look at drugs that may limit the progression of MS. Researchers have been recruiting people with secondary progressive MS from across the UK, but are still in need of more people to volunteer to take part. 

18 February 2016

Encouraging results from ozanimod drug trial

Ozanimod is a drug that works in a similar way to Gilenya (fingolimod) but with fewer side effects according to recently published research.

17 February 2016

Drug for primary progressive MS takes a step towards licensing in the USA

Ocrelizumab has become the first new medicine for MS to be granted a special status that could speed up approval by the American drug regulators

11 February 2016

New campaign launched to legalise cannabis for medicinal use including for multiple sclerosis

News item on campaign to legalise medicinal cannabis.

27 January 2016

Phase II study of epilepsy drug shows promise in optic neuritis

Results of a small study just published suggest that the epilepsy drug phenytoin may have a neuroprotective effect and could potentially be beneficial in people with MS.

18 January 2016

MS Trust welcomes Panorama stem cell report, announces plans to audit stem cell services

Last night (Monday 18 January 2016) you may have seen that BBC1 broadcast an episode of Panorama called “Can you stop my multiple sclerosis?”. The programme explored the use of stem cell therapy at Sheffield Teaching Hospitals to treat people with multiple sclerosis. The MS Trust was glad that the programme took a considered, unsensationalist approach to what has sometimes proved to be a controversial issue.

Latest news
13 January 2016

Why the MS Trust is not endorsing the new NICE Quality Standard for MS

The MS Trust was closely involved in the development process, contributing to all stages of scoping and consultation. We welcome elements of the standard, in particular statements 2, 3 and 6 which, if implemented, will be a real step forward in ensuring that people with MS get the specialist input they need (see below). But, after careful consideration, we decided we could not endorse the final document.

31 December 2015

MS Trust congratulates MS neurologist for New Year’s honour

Prof Alastair Compston has been awarded a Commander of the Order of the British Empire (CBE) in the New Year’s Honours.

31 December 2015

Small study shows high doses of vitamin D may modify the immune system in MS

Results from a small study just published has demonstrated taking 10,000 IU of vitamin D appears to be safe for people with MS and could reduce the proportion of the immune cells that are thought to drive MS activity. 

22 December 2015

Band 8 Lead MS Nurse on NHS Jobs

Plymouth Hospital NHS Trust is currently advertising for a Band 8 Lead MS Nurse on NHS Jobs. A great opportunity working as a member of the MS team, the post holder will provide leadership to the MS nurses and look for new and innovative ways to meet the increasing demands of the service.

20 November 2015

Judge rules on withdrawing treatment

A judge from the Court of Protection has ruled that doctors can withdraw treatment from a woman with MS described as being in a "minimally conscious state" and having little awareness of the outside world.

Cost of emergency hospital admissions in MS
17 November 2015

NHiS and MS Trust report highlights the costs of emergency hospital care for people with MS

Many people with MS have to go to hospital for emergency treatment for preventable conditions, according to a new report  published today by the MS Trust and NHiS.

09 November 2015

Large-scale MS Trust evaluation reveals that vitally important MS services face critical challenges

A major new MS Trust report reveals that vital MS services face increasing pressures which could lead to inequities in care.

Congratulations to all the winners of the QuDoS awards
06 November 2015

Revealed: the winners of the inaugural QuDos awards for MS services

MS specialist nurses, neurologists, allied health professionals and multi-disciplinary teams from across the UK have been recognised in the first ever QuDos awards for quality in the delivery of MS services.

MS news
23 October 2015

Tysabri unsuccessful in secondary progressive MS trial

Preliminary results announced in a press release report that treatment with Tysabri did not slow down the gradual increase in disability experienced by people with secondary progressive MS.

20 October 2015

ECTRIMS 2015 round up

Overview of some of the research highlights reported at the ECTRIMS 2015 conference in Barcelona.

09 October 2015

Drug for primary progressive MS shows positive result

According to topline results released by the manufacturer, ocrelizumab reduced the risk of increased disability in primary progressive MS by 24% compared to placebo. In relapsing remitting MS, ocrelizumab reduced the number of relapses by 50% compared to interferon beta 1a (Rebif)

14 September 2015

Neurologists move toward earlier treatment for MS

People with relapsing remitting MS should be considering starting disease modifying treatment as early as possible and be active partners in treatment choices according to newly revised guidelines published today by the ABN.

10 September 2015

Smoking leads to earlier transition to secondary progressive MS

A study has reported that smokers who continued to smoke after being diagnosed with relapsing remitting MS reached the transition to secondary progressive MS more quickly than those who gave up smoking.

04 September 2015

Take part in a survey on Living with Medicines

The survey will take 10-15 minutes to complete and all responses are anonymous.

28 August 2015

Latest figures showing variation in access to neurology services come as no surprise

Latest figures showing variation in access to neurology services come as no surprise

26 August 2015

Link between vitamin D and MS onset

People with genes that cause them to have low levels of vitamin D are more likely to develop MS according to new research

06 August 2015

PML risk with Gilenya prompts update to US prescribing information

The FDA has announced that it will update the information for Gilenya (fingolimod) after two possible cases of PML in people with MS taking this disease modifying drug in the USA.

03 August 2015

Draft recommendations on vitamin D published

The Scientific Advisory Committee on Nutrition (SACN), an independent body which advises the Government on diet, nutrition and health matters, have published their draft recommendations on vitamin D which are now out for public consultation until 23 September.

25 June 2015

Report shows people with advanced MS miss out on access to palliative care services.

Triggers for palliative care, a report by Marie Curie, suggests that people with neurological conditions including MS are missing out on care that can make a real difference to quality of life. It shows that there is limited understanding from both health professionals and the public of what palliative care can offer, who can benefit and when the time is right time to access this holistic care.

22 April 2015

Two treatments identified which may have a role in myelin repair

Laboratory studies have shown two treatments currently used to treat skin conditions may have the potential to be developed into therapies to repair myelin in people with MS. However, this is very early research in animals and human cells, so the press coverage reporting the treatments as a 'cure', or 'reversing' or 'stopping' MS is somewhat premature.

02 April 2015

Positive interim results from major UK study on MS drugs

Results of the analysis of the 6 year data of the Department of Health (DH) MS Risk-sharing Scheme (RSS), published in the Lancet Neurology today, show that the disease modifying drugs Avonex, Betaferon, Copaxone and Rebif are cost effective and are clinically effective in reducing the progression of the disease in people with relapsing remitting multiple sclerosis (MS).

31 March 2015

MS- SMART- secondary progressive MS trial starts recruiting

Researchers have started to recruit 440 people with secondary progressive MS across the UK for a trial that will look at drugs that may limit the progression of MS.

03 March 2015

Stem cells - hope for the future?

In the last couple of days, several of the national newspapers have reported "miraculous" results from stem cell treatments for people with MS. Headlines included "Stem cell reboot has MS patients dancing", "'Miracle' stem cell therapy reverses multiple sclerosis". But what are the facts behind these headlines?

29 January 2015

Research into MS and other health conditions published

Having multiple sclerosis unfortunately doesn't prevent people from developing other health conditions and these may have an impact on MS symptoms and treatment. An international study is trying to identify the most common conditions (comorbidities) experienced by people who have MS.

20 January 2015

Stomach bacteria might protect against MS

A study in Australia suggests that women infected with the common stomach bug Helicobacter pylori (H.pylori) have a lower risk of developing multiple sclerosis.

14 January 2015

MS patients are 'invisible' in most Clinical Commissioning Groups (CCGs)

The Invisible Patients, a new report published today by the Neurological Alliance has found that people with MS in England are unknown to their local Clinical Commissioning Groups. The Neurological Alliance sent Freedom of Information requests to all CCGs, to ascertain how aware they are of neurological conditions in their patch.

13 January 2015

Plegridy will be available on the NHS in Scotland

The Scottish Medicines Consortium (SMC) has approved peginterferon beta-1a (Plegridy) as a treatment for relapsing remitting multiple sclerosis on the NHS in Scotland

30 December 2014

Encouraging results from stem cell trial

Interim results from a five year stem cell study suggest the treatment could eventually be an effective way to manage relapsing remitting MS.

01 December 2014

Fingolimod (Gilenya) not effective in primary progressive MS

Fingolimod (Gilenya) was no better than placebo at reducing measures of progression in people with primary progressive MS according to information announced today.

28 November 2014

Tenth drug for relapsing remitting MS now available in the UK

Dimethyl fumarate was approved by NICE (National Institute for Health and Care Excellence) in August. Following a recommendation by NICE, the NHS in England and Wales has three months in which to prepare for prescribing the drug. 

23 October 2014

PML case reported for dimethyl fumarate (Tecfidera)

A case of PML (progressive multifocal leukoencephalopathy) has been reported in a person who had been taking dimethyl fumarate (Tecfidera).

21 October 2014

No link between vaccination and risk of MS

This new study found no long term association between any vaccines, including hepatitis B and HPV (human papillomavirus), and an increased risk of developing MS, for up to three years following vaccination.

15 October 2014

New NICE Guideline information for the public now available

Following the recent publication of the NICE Guideline for the management of MS in primary and secondary care (Clinical Guideline 186), NICE have now published their information for the public.

14 October 2014

Fingolimod (Gilenya) eligibility extended in Scotland

The Scottish Medicines Consortium (SMC), which issues guidance on whether treatments should be funded by NHS Scotland, has announced that fingolimod can now also be prescribed for people with rapidly evolving severe relapsing remitting MS (RES RRMS).

08 October 2014

New NICE Guideline for MS published today

Today sees the publication of the first revision since 2003 of the NICE Guideline for the management of MS in primary and secondary care (Clinical Guideline 186).

03 October 2014

People with MS are encouraged to get seasonal flu jab

The seasonal flu vaccination is now available to people who fall into at-risk groups, which includes anyone with a neurological condition such as multiple sclerosis, those over 65, and the main carers of a disabled person.

29 September 2014

Amantadine (Symmetrel, Lysovir) may be out of stock due to manufacturing delays

Anyone currently taking amantadine, sometimes prescribed for fatigue in MS, may want to check with their pharmacist to ensure there will be stocks ready for their next prescription.

05 September 2014

Fampridine not recommended for the NHS in Wales

The Welsh drug regulator has announced that fampridine (Fampyra) is not a cost effective treatment for MS-related walking problems.


04 September 2014

Manifesto 2015: a call to action for neurology.

With less than a year to go before the next general election, the Neurological Alliance has launched its manifesto. This sets out some key policy ‘asks’ that are applicable across the full spectrum of neurological conditions including MS. 

27 August 2014

Dimethyl fumarate (BG-12, Tecfidera) - NICE confirms approval in final guidance

Dimethyl fumarate (BG-12, Tecfidera) will start to be available on the NHS in England and Wales from November following final guidance from NICE (National Institute for Health and Care Excellence).

15 August 2014

Sativex approved for use on the NHS in Wales

Sativex (nabiximols) has been recommended by the All Wales Medicines Strategy Group (AWMSG) for use within NHS Wales for the treatment of MS-related spasticity.


11 August 2014

MS Trust congratulates Stephanie Millward on her latest medal haul

Swimmer with MS wins 7 medals at the IPC Swimming European Championships.

08 August 2014

The right words? - receiving a diagnosis of MS

A recent article in the Irish Times explores the role of language in the diagnosis of life-challenging conditions – including multiple sclerosis.

06 August 2014

Could HIV drugs help treat or prevent MS?

A large study has shown that people with HIV appear to be at a significantly lower risk of developing MS.

24 July 2014

Plegridy approved in Europe

Peginterferon beta 1a (Plegridy), a new treatment for relapsing remitting MS, has been licensed by the European Commission.

04 July 2014

New report on bowel management in MS launched on Bowel Independence Day

The MS Trust has worked together with other organisations to ask people with MS and MS specialist nurses how bowel problems are currently being managed and how this can be improved. The report is published today.

12 June 2014

Fingolimod (Gilenya) licence extended

The European Commission has approved the extension of the licence for fingolimod to allow greater access to the drug for people with highly active relapsing remitting multiple sclerosis.

10 June 2014

A backward step for MS services: the draft NICE MS Clinical Guideline

The MS Trust is concerned that recommendations in the NICE Clinical Guideline may set back the availability and quality of care for people with multiple sclerosis.


09 June 2014

Significant shortfall in the number of UK MS specialist nurses shown by MS Trust report

A report published today by the MS Trust finds that there is a clear shortfall of at least 126 MS specialist nurses in the UK, with nurses routinely managing 550 patients as opposed to the recommended caseload of approximately 300 people per nurse.

09 June 2014

MS research using stem cells gives hope for the future

The MS Trust takes to the radio to explain the current research trials.

29 April 2014

NICE publishes draft of revised MS Clinical Guideline April 2014

NICE has published a draft of the revised clinical guideline Management of multiple sclerosis in primary and secondary care and has invited comments from registered stakeholders.

28 April 2014

Survey suggests access to disease modifying drugs is not universal

A letter to The Telegraph today suggests that more than half of people with MS in the UK may not be getting access to treatments they need.

25 April 2014

New health app launched to help people monitor their MS

A free app (SymTrac) that enables people to track their MS over time was launched yesterday.

07 April 2014

Dimethyl fumarate (BG-12, Tecfidera) approved for use by the NHS in Scotland

The Scottish Medicines Consortium (SMC) has approved dimethyl fumarate (BG-12, Tecfidera) as a treatment for relapsing remitting multiple sclerosis on the NHS in Scotland.

The MS Trust welcomes the decision by SMC.

19 March 2014

Small trial of simvastatin shows promise as treatment for MS

Brain volume loss and progression of the condition were both slowed and quality of life was improved

140 people with secondary progressive multiple sclerosis took either high dose simvastatin (80mg/day) or placebo in this two year, phase II clinical trial. MRI scans measured brain volume during the course of the study, disability was measured using the EDSS scale and participants completed questionnaires to measure the impact of MS on day-to-day living. Simvastatin was well tolerated by the participants.

17 January 2014

Family risk recalculated

Research in Sweden suggests the risk of a relative of someone with MS also getting the condition is lower than previously thought.

08 November 2013

Getting ready for winter

As winter approaches, advice has been published about remaining healthy and warm during the cold weather.

08 November 2013

MS in black Caribbean people

A study at Kings College Hospital in London has found that people with MS of Caribbean descent had more rapid progression than white people.

04 October 2013

Identification of more genes linked to risk of MS

Research published in the journal Nature Genetics has identified 48 new genes that may play a part in susceptibility to MS.

04 October 2013

Worldwide increase in MS

There are now 2.3 million people with MS around the world according to a report that accompanies the new edition of the Atlas of MS published by the Multiple Sclerosis International Federation (MSIF).

28 December 2012

Could the eye be a window into multiple sclerosis?

Recent research suggests that a detailed eye scan, optical coherence tomography, could be an effective way of monitoring multiple sclerosis.

18 June 2012

Jack Osbourne diagnosed with MS

Jack Osbourne, the son of Black Sabbath frontman Ozzy and former X Factor judge Sharon, was diagnosed earlier this year after he lost 60% of the vision in his right eye.

26 February 2010

New assisted suicide guidelines published

The Director of Public Prosecutions (DPP) has issued new guidelines on whether someone will be prosecuted for helping someone to die.